 BioCardia, Inc. NasdaqCM: BCDA the Company, a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the pricing of its public offering of 4,762,000 shares of common stock at a price to the public of 2.10 per share. BioCardia expects to receive gross proceeds of 10 million, before deducting underwriting discounts and commissions and other estimated offering expenses. BioCardia has granted the underwriters a 45-day option to purchase up to 714,190 additional shares of common stock, at the public offering price to cover over-allotments, if any. 